Advances in the genomic and metabolic landscapes of acute myeloid leukemia

References

[1] Döhner H,Wei AH,Appelbaum FR.et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN Blood 2022 140 1345 77

[2] Khattab S,Berisha A,Baran N,Piccaluga PP. Rat sarcoma virus family genes in acute myeloid leukemia: pathogenetic and clinical implications Biomedicines 2025 13 202 PMC11760468

[3] Vosberg S,Greif PA. Clonal evolution of acute myeloid leukemia from diagnosis to relapse Genes Chromosomes Cancer 2019 58 839 49 PMC6852285

[4] Kamath-Loeb AS,Shen JC,Schmitt MW.et al. Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation duplex sequencing Leuk Res 2022 115 106822 PMC9014797

[5] Papaemmanuil E,Gerstung M,Bullinger L.et al. Genomic classification and prognosis in acute myeloid leukemia N Engl J Med 2016 374 2209 21 PMC4979995

[6] Tyner JW,Tognon CE,Bottomly D.et al. Functional genomic landscape of acute myeloid leukaemia Nature 2018 562 526 31

[7] Haferlach T,Walter W. Challenging gold standard hematology diagnostics through the introduction of whole genome sequencing and artificial intelligence Int J Lab Hematol 2023 45 156 62

[8] Jaiswal S,Fontanillas P,Flannick J.et al. Age-related clonal hematopoiesis associated with adverse outcomes N Engl J Med 2014 371 2488 98 PMC4306669

[9] Stein EM,DiNardo CD,Fathi AT.et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib Blood 2019 133 676 87 PMC6384189

[10] DiNardo CD,Stein EM,de Botton S.et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML N Engl J Med 2018 378 2386 98

[11] Pikman Y,Puissant A,Alexe G.et al. Targeting MTHFD2 in acute myeloid leukemia J Exp Med 2016 213 1285 306 PMC4925018

[12] Ye J,Fan J,Venneti S.et al. Serine catabolism regulates mitochondrial redox control during hypoxia Cancer Discov 2014 4 1406 17 PMC4258153

[13] Mussai F,De Santo C,Abu-Dayyeh I.et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment Blood 2013 122 749 58 PMC3731930

[14] Böttcher M,Renner K,Berger R.et al. D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization Oncoimmunology 2018 7 e1445454 PMC5993507

[15] Moschoi R,Imbert V,Nebout M.et al. Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy Blood 2016 128 253 64

[16] Zeng AGX,Iacobucci I,Shah S.et al. Single-cell transcriptional atlas of human hematopoiesis reveals genetic and hierarchy-based determinants of aberrant AML differentiation Blood Cancer Discov 2025 6 307 24 PMC12209776

[17] Hörst K,Kühn C,Haferlach C,Haferlach T,Khoury JD. Genetic studies in clonal haematopoiesis, myelodysplastic neoplasms and acute myeloid leukaemia- a practical guide to WHO-HAEM5 Med Genet 2024 36 21 9 PMC11006295

[18] Genovese G,Kähler AK,Handsaker RE.et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence N Engl J Med 2014 371 2477 87 PMC4290021

[19] Steensma DP,Bejar R,Jaiswal S.et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes Blood 2015 126 9 16 PMC4624443

[20] Pourebrahim R,Montoya RH,Akiyama H.et al. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice Cell Rep Med 2024 5 101558 PMC11148800

[21] Ding L,Ley TJ,Larson DE.et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing Nature 2012 481 506 10

[22] Shlush LI,Mitchell A,Heisler L.et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells Nature 2017 547 104 8

[23] Morita K,Wang F,Jahn K.et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics Nat Commun 2020 11 5327 PMC7577981

[24] Ruhnke L,Bill M,Zukunft S.et al. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia Blood Adv 2025 9 1392 404 PMC11960536

[25] Mrózek K,Kohlschmidt J,Blachly JS.et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an alliance study Leukemia 2023 37 788 98 PMC10079544

[26] Lachowiez CA,Long N,Saultz J.et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia Blood Adv 2023 7 1899 909 PMC10172873

[27] Chomczyk M,Gazzola L,Dash S.et al. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment Front Pharmacol 2024 15 1409210 PMC11330794

[28] DiNardo CD,Tiong IS,Quaglieri A.et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML Blood 2020 135 791 803 PMC7068032

[29] Losman JA,Looper RE,Koivunen P.et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible Science 2013 339 1621 5

[30] Stein EM,DiNardo CD,Pollyea DA.et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Blood 2017 130 722 31

[31] Roboz GJ,DiNardo CD,Stein EM.et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia Blood 2020 135 463 71 PMC7019193

[32] Montesinos P,Recher C,Vives S.et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia N Engl J Med 2022 386 1519 31

[33] Amatangelo MD,Quek L,Shih A.et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response Blood 2017 130 732 41 PMC5553578

[34] Ernst T,Chase AJ,Score J.et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nat Genet 2010 42 722 6

[35] Jones CL,Stevens BM,D’Alessandro A.et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells Cancer Cell 2018 34 724 740.e4 PMC6280965

[36] Farge T,Saland E,de Toni F.et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism Cancer Discov 2017 7 716 35 PMC5501738

[37] Lagadinou ED,Sach A,Callahan K.et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells Cell Stem Cell 2013 12 329 41 PMC3595363

[38] Wang T,Yu H,Hughes NW.et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras Cell 2017 168 890 903.e15 PMC5445660

[39] Pollyea DA,Stevens BM,Jones CL.et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia Nat Med 2018 24 1859 66 PMC7001730

[40] Sharon D,Cathelin S,Mirali S.et al. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response Sci Transl Med 2019 11 eaax2863

[41] Sykes DB,Kfoury YS,Mercier FE.et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia Cell 2016 167 171 186.e15

[42] Pacold ME,Brimacombe KR,Chan SH.et al. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate Nat Chem Biol 2016 12 452 8 PMC4871733

[43] Zhu X,Huang W,Zhang M,Tao Y,Zhang H. The ATF4/PSAT1/JNK signaling axis suppresses ferroptosis to drive venetoclax resistance in AML Exp Cell Res 2026 460 115045

[44] Brcic A,Lalic H,Smoljo T.et al. Roles of RRM2 and RRM2B in pyrimidine stress responses and differentiation of acute myeloid leukemia cells Cell Death Discov 2026 12 271 PMC13243657

[45] Takahashi S. Targeting nucleotide metabolism and epigenetic regulation to overcome the differentiation blockade in AML Leuk Res Rep 2026 25 100586 PMC13094505

[46] Cramer SL,Saha A,Liu J.et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth Nat Med 2017 23 120 7 PMC5218918

[47] Gout PW,Buckley AR,Simms CR,Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x_c^- cystine transporter: a new action for an old drug Leukemia 2001 15 1633 40

[48] Magtanong L,Ko PJ,To M.et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state Cell Chem Biol 2019 26 420 432.e9 PMC6430697

[49] Gao M,Yi J,Zhu J.et al. Role of mitochondria in ferroptosis Mol Cell 2019 73 354 363.e3 PMC6338496

[50] Han X,Wang K,Ma W.et al. A ketogenesis-ferroptosis axis maintains leukemic stem cell survival and leukemia progression Cell Stem Cell 2026 33 1016 1030.e6

[51] Zhang T,Cao Z,Gao K.et al. PIEZO1 is required for acute myeloid leukemia progression and leukemia stem cell maintenance via HIF1A-SLC7A11 axis-mediated ferroptosis defense Adv Sci 2026 e75648

[52] Chrest BR,Fisher-Wellman KH. Re-evaluating the rationale for targeting oxidative phosphorylation in acute myeloid leukemia Biochem J 2026 483 907 25 PMC13265131

[53] Narote S,Desai SA,Patel VP,Deshmukh R,Raut N,Dapse S. Identification of new immune target and signaling for cancer immunotherapy Cancer Genet 2025 294-295 57 75

[54] Fraietta JA,Nobles CL,Sammons MA.et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells Nature 2018 558 307 12

[55] Khattab S,El Sorady M,El-Ghandour A,Visani G,Piccaluga PP. Hematopoietic and leukemic stem cells homeostasis: the role of bone marrow niche Explor Target Antitumor Ther 2024 5 1027 55 PMC11438561

[56] Luu M,Pautz S,Kohl V.et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes Nat Commun 2019 10 760 PMC6377655

[57] Payen VL,Mina E,Van Hée VF,Porporato PE,Sonveaux P. Monocarboxylate transporters in cancer Mol Metab 2020 33 48 66 PMC7056923

[58] Bottomly D,Long N,Schultz AR.et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia Cancer Cell 2022 40 850 864.e9

[59] Hourigan CS. Role of MRD testing in acute myeloid leukemias. What is the status and how to get there? Semin Hematol 2025;62:431-7

[60] de Botton S,Montesinos P,Schuh AC.et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial Blood 2023 141 156 67 PMC10644040

[61] Brattås MK,Hatfield KJ,Paulsen Rye K,Reikvam H. Metabolomics profiling of acute myelogenous leukemia patients to identify systemic differences associated with in vitro sensitivity to SYK inhibitors Metabolomics 2026 22;51 PMC13090287

[62] Moses L,Pachter L. Museum of spatial transcriptomics Nat Methods 2022 19 534 46

[63] Schwamborn K,Caprioli RM. Molecular imaging by mass spectrometry-looking beyond classical histology Nat Rev Cancer 2010 10 639 46

[64] Galloway-Peña JR,Smith DP,Sahasrabhojane P.et al. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia Cancer 2016 122 2186 96 PMC5574182

[65] Bagaloni I,Visani A,Biagiotti S.et al. Metabolic switch and cytotoxic effect of metformin on burkitt lymphoma Front Oncol 2021 11 661102 PMC8454268

[66] Gatua M,Navari M,Ong’ondi M.et al. Molecular profiling of kenyan acute myeloid leukemia patients Front Genet 2022 13 843705 PMC9274457